Skip to main content

Table 1 Outcomes extracted from the randomized clinical trials and included into the mixed treatment comparison

From: Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

Study All-cause mortality Incidence of proven/probable IFI overall Incidence of proven/probable IA Incidence of proven IC Incidence of OLAT use
Winston 2003 [29]      
Fluconazole 28/67 (42%) 17/67 (25%) 8/67 (12%) 8/67 (12%) Not reported
Itraconazole 32/71 (45%) 6/71 (8%) 3/71 (4%) 2/71 (3%) Not reported
Marr 2004 [26]      
Fluconazole 44/148 (30%) 25/148 (17%) 20/148 (14%) 5/148 (3%) 25/148 (17%)
Itraconazole 55/151 (36%) 19/151 (13%)a 16/151 (11%) 4/151 (3%) 19/151 (13%)
Ullmann 2007 [27]      
Fluconazole 59/299 (20%) 27/299 (9%) 21/299 (7%) 4/299 (1%) 29/288 (10%)
Posaconazole 58/301 (19%) 16/301 (5%) 7/301 (2%) 4/301 (1%) 31/291 (11%)
Wingard 2010 [28]      
Fluconazole 59/295 (20%) 24/295 (8%) 17/295 (6%) 5/295 (2%) 89/295 (30%)
Voriconazole 57/305 (19%) 14/305 (5%) 9/305 (3%) 3/305 (1%) 73/305 (24%)
Marks 2011 [10]      
Itraconazole 44/241 (18%) 5/241 (2%) 5/241(2%) 0/241 (0%) 101/241 (42%)
Voriconazole 40/224 (18%) 3/224 (1%) 1/224 (0.4%) 2/224 (1%) 67/224 (30%)
  1. IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
  2. aOne patient developed both proven IC and probable IA, which was counted as a single IFI instead of 2 separate IFIs.